

Figure S1. Collagen characteristics evaluated on day 6. \*P<0.05 vs. PI, \*\*P<0.01 vs. PI, \*\*\*P<0.001 vs. PI, #P<0.05 vs. SES-low, ##P<0.01 vs. SES-low, ###P<0.001 vs. SES-low, ♣P<0.05 vs. SES-low + G, ♣♣P<0.01 vs. SES-low + G, ♣♣♣P<0.001 vs. SES-low + G, ♠P<0.05 vs. SES-high, ♠♠P<0.001 vs. SES-high, ♠♠P<0.01 vs. SES-high + G, ♠♠♠P<0.001 vs. SES-high + G, ♠P<0.05 vs. S, ♠♠P<0.01 vs. S. SES, superoxidized electrolyzed solution; NF, nitrofurazone; PI, placebo; S, silver sulfadiazine; and G, gel.




Figure S2. Collagen characteristics evaluated on day 9. #P<0.05 vs. SES-low, \*P<0.05 vs. SES-low + G, \*\*P<0.01 vs. SES-low + G, \*\*\*P<0.001 vs. NF, ♣P<0.05 vs. S, ♠P<0.01 vs. S, ♣♣P<0.01 vs. S, ♠♠P<0.01 vs. NF, ♣♣♣P<0.001 vs. NF, ♠♠P<0.05 vs. S, ♣♣♣P<0.001 vs. S. SES, superoxidized electrolyzed solution; NF, nitrofurazone; PI, placebo; S, silver sulfadiazine; and G, gel.




Figure S3. Collagen characteristics evaluated on day 18. \*\*P<0.01 vs. Pl, \*\*\*P<0.001 vs. Pl, #P<0.05 vs. SES-low, ##P<0.01 vs. SES-low, ♣P<0.05 vs. SES-high, \*\*P<0.01 vs. NF, ♠P<0.05 vs. S, ♪P<0.01 vs. S. SES, superoxidized electrolyzed solution; NF, nitrofurazone; Pl, placebo; S, silver sulfadiazine; and G, gel.




Figure S4. Representative Masson's staining, Day (A) 9 and (B) 18. Magnification, x40. SES, superoxidized electrolyzed solution; NF, nitrofurazone; PI, placebo; S, silver sulfadiazine; and G, gel.

